Citrulline
Phase 2Small molecule
Citrulline is one of 81 small molecule programs targeting Toxicity. It is currently in Phase 2.
3
Indications
6
Total Trials
0
Active Trials
80
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
272 competitors in Sickle Cell Disease
#DrugCompanyPhaseTrials
1Exjade
NovartisPhase 3
Brilinta
AstraZenecaPhase 3
Campath
GGenzyme, a Sanofi Company
Phase 3
Ritalin
NovartisPhase 3
Cysteine Hydrochloride
NovartisPhase 3
Eliquis
Bristol-Myers SquibbPhase 3
Oxbryta
GGlobal Blood Therapeutics
Phase 3
Aqvesme
AAgios Pharmaceuticals, Inc.
Phase 3
Effient
CCosette Pharmaceuticals, Inc.
Phase 3
Xarelto
WWim Janssens
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Preeclampsia1 trial
Acute Chest Syndrome1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Citrulline. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- NNantes University Hospital